Lipophilic statins are associated with reduced mortality in epithelial ovarian cancer.
-
AACR 2020 – From high cholesterol to ovarian cancer, is it time to repurpose statins? -
Minimal invasive surgery increases risk for death in gynecologic cancers 2 studies on ovarian and cervical cancers reported higher risk vs open surgery.
-
Ovarian cancer: novel therapy delays progression Adding berzosertib to chemotherapy extends PFS in randomized trial.
-
ASCO 2020 – Ovarian cancer: maintenance olaparib extends OS more than 1 year, setting new standard Final OS results of SOLO2 trial report on maintenance olaparib for platinum-sensitive relapsed ovarian cancer with BRCA mutation.
-
Early ovarian cancer: fertility sparing and radical surgery yield similar outcomes High-risk disease has worse prognosis irrespective of surgery type.
-
Merkel cell carcinoma: neoadjuvant nivolumab shows promising activity Findings from phase 1/2 CheckMate 358 study.
-
FDA approves maintenance olaparib-bevacizumab for HRD-positive advanced ovarian cancer FDA also approved companion test based on randomized, phase 3 PAOLA-1 trial.
-
FDA approves first-line maintenance niraparib in ovarian cancer The approval was based on phase 3 PRIMA trial.
-
Platinum-sensitive recurrent ovarian cancer: chemotherapy-bevacizumab combo tops standard Shows superior survival in phase 3 AGO-OVAR 2.21 study.
-
Recurrent ovarian cancer: nivolumab plus ipilimumab shows response in phase 2 The response is not durable in most patients, and further exploration is warranted.
-
Even short-term breastfeeding is linked to reduced risk for ovarian cancer Fewer than 3 months of breastfeeding per child confers benefit.
-
SGO 2020 — High bone loss, osteoporosis risk in younger patients with gynecologic cancer Young patients may warrant early bone density evaluation.
-
SGO 2020 — Advanced ovarian cancer: concomitant increase in neoadjuvant chemotherapy use and survival A cross-sectional analysis of women from the National Cancer Database.
-
ESMO updates ovarian cancer guidelines Maintenance therapy with PARP inhibitors approved for relapsed epithelial cancer.